For the roughly 6 million Americans living with atrial fibrillation, catheter ablation has become an increasingly common ...

The National Consumer Commission (NCC) has notified South African health facilities and medical practitioners about a recall of Boston Scientific medical devices.

J&J has reported interim 12-month results from the VARIPURE study, assessing the effectiveness and safety of its Varipulse PFA platform in first-time users.

Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.

Pulse Biosciences recently advanced its nPulse Cardiac Catheter Ablation System by enrolling the first patients in its pivotal NANOPULSE-AF IDE study for drug-resistant paroxysmal atrial fibrillation, ...

The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.

RESET-PSVT is intended to generate prospective evidence to inform the real-world use of recently approved CARDAMYST and demonstrate its potential impact on the acute management of PSVT. Results are ...

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...

Pulse Biosciences is keeping the noise level up by announcing the enrollment of the first patients in the NANOPULSE-AF study, ...

From its first use in 1998, to its status as a routine management strategy when medication is not an option, our understanding of catheter ablation for AF has grown immensely 4. Over the past 28 years ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation ...

On Wednesday, March 25, members and guests of the Pattaya City Expats Club were treated to a practical, case-driven lesson in heart rhythm disorders as “Doc” Martyn Green used a real consultation to ...